Therefore, our results suggested that ADLE is a potential therapeutic drug for decreasing hyperlipidemia and improving insulin sensitivity in patients with NAFLD and with type 2 diabetes. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.